Trachoma: An update on prevention, diagnosis, and treatment

Current Opinion in Ophthalmology

Volumn 23, Issue 4, 2012, Pages 288-295

  Bhosai, Satasuk Joy ^a   Bailey, Robin L ^b   Gaynor, Bruce D ^a   Lietman, Thomas M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

azithromycin; chlamydia; confocal microscopy; neglected tropical disease; nucleic acid amplification tests; trachoma

Indexed keywords

AZITHROMYCIN;

ANTIBIOTIC RESISTANCE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONFOCAL MICROSCOPY; COST OF ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG HALF LIFE; ENDEMIC DISEASE; ETHIOPIA; EYE SURGERY; HUMAN; IMMUNOPATHOLOGY; INFECTION CONTROL; MORTALITY; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TRACHOMA; TRICHIASIS;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RNA, RIBOSOMAL; TRACHOMA;

EID: 84862584029     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835438fc     Document Type: Review

References (79)

1. West S. Trachoma and antibiotic use: the 'A' in SAFE. Expert Rev Anti Infectv Ther 2012; 10:75-83.
2. Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009; 93:563-568.
3. Wright HR, Turner A, Taylor HR. Trachoma. Lancet 2008; 371:1945-1954.
4. Kumaresan J, Mecaskey J. The global elimination of blinding trachoma: progress and promise. Am J Trop Med Hyg 2003; 24-28.
5. Frick KD, Hanson CL, Jacobson GA. Global burden of trachoma and economics of the disease. Am J Trop Med Hyg 2003; 69:1-10.
6. Kuper H, Solomon AW, Buchan J, et al. A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis 2003; 3:372-381.
7. Hu VH, Harding-Esch EM, Burton MJ, et al. Epidemiology and control of trachoma: systematic review. Trop Med Int Health 2010; 15:673-691.
8. Polack S, Brooker S, Kuper H, et al. Mapping the global distribution of trachoma. Bull World Health Organ 2005; 83:913-919.
9. Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ 1987; 65:477-483.
10. Abu el-Asrar AM, Geboes K, Missotten L. Immunology of trachomatous conjunctivitis. Bull Soc Belge Ophtalmol [no volume] 2001.
11. Guzey M, Ozardali I, Basar E, et al. A survey of trachoma: the histopathology and the mechanism of progressive cicatrization of eyelid tissues. Ophthalmologica 2000; 214:277-284.
12. Guzey M, Satici A, Karaman SK, et al. The effect of topical cyclosporine treatment on corneal thickness in patients with trachomatous dry eye. Clin Exp Optom 2009; 92:349-355.
13. Burton M, Kinteh F, Jallow O, et al. A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in The Gambia. Br J Ophthalmol 2005; 89:1282-1288.
14. Lietman TM, Dawson CR, Osaki SY, Zegans ME. Clinically active trachoma versus actual chlamydial infection. Med J Aust 2000; 172:93-94.
15. Bird M, Dawson CR, Schachter JS, et al. Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? J Infect Dis 2003; 187:1669-1673.
16. Burton MJ, Rajak SN, Bauer J, et al. Conjunctival transcriptome in scarring trachoma. Infect Immun 2011; 79:499-511.
17. Hu VH, Massae P, Weiss HA, et al. Bacterial infection in scarring trachoma. Invest Ophthalmol Vis Sci 2011; 52:2181-2186.
18. Grassly NC, Ward ME, Ferris S, et al. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis 2008; 2:e341.
19. Bailey R, Duong T, Carpenter R, et al. The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 1999; 479-486.
20. Burton MJ, Ramadhani A, Weiss HA, et al. Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines. Infect Immun 2011; 79:4977-4983.
21. Burton MJ, Hu VH, Massae P, et al. What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting. Invest Ophthalmol Vis Sci 2011; 52:6012-6017.
22. Hu VH, Weiss HA, Ramadhani AM, et al. Innate immune responses and modified extracellular matrix regulation characterize bacterial infection and cellular/connective tissue changes in scarring trachoma. Infect Immun 2012; 80:121-130.
23. Grayston JT, Wang SP, Woolridge RL, Alexander ER. Prevention of trachoma with vaccine. Arch Environ Health 1964; 8:518-526.
24. Wang SP, Grayston JT. Pannus with experimental trachoma and inclusion conjunctivitis agent infection of Taiwan monkeys. Am J Ophthalmol 1967; 63 (Suppl):1133-1145.
25. Wang SP, Grayston JT, Alexander ER. Trachoma vaccine studies in monkeys. Am J Ophthalmol 1967; 63 (Suppl):1615-1630.
26. Kari L, Whitmire WM, Olivares-Zavaleta N, et al. A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med 2011; 208:2217-2223.
27. Keenan JD, Lakew T, Alemayehu W, et al. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Arch Ophthalmol- Chic 2011; 129:512-513.
28. Munoz B, Stare D, Mkocha H, et al. Can clinical signs of trachoma be used after multiple rounds of mass antibiotic treatment to indicate infection? Invest Ophthalmol Vis Sci 2011; 52:8806-8810.
29. Stare D, Harding-Esch E, Munoz B, et al., Group OBOPS. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: The Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmic Epidemiol 18:20-29.
30. Michel C-EC, Roper KG, Divena MA, et al. Correlation of clinical trachoma and infection in Aboriginal communities. PLoS Negl Trop Dis 2011; 5:e986.
31. Solomon AW, Foster A, Mabey DCW. Clinical examination versus Chlamydia trachomatis assays to guide antibiotic use in trachoma control programmes. Lancet Infect Dis 2006; 6:5-6; author reply 7-8.
32. Keenan JD, Ayele B, Gebre T, et al. Ribosomal RNA evidence of ocular Chlamydia trachomatis infection following 3 annual mass azithromycin distributions in communities with highly prevalent trachoma. Clin Infect Dis 2012; 54:253-256.
33. See CW, Alemayehu W, Melese M, et al. How reliable are tests for trachoma?: A latent class approach. Invest Ophthalmol Vis Sci 2011; 52:6133-6137.
34. Yang JL, Schachter J, Moncada J, et al. Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma. Br J Ophthalmol 2007; 91:293-295.
35. Harding-Esch EM, Holland MJ, Schémann J-F, et al. Diagnostic accuracy of
36. Hu VH, Massae P, Weiss HA, et al. In vivo confocal microscopy of trachoma in relation to normal tarsal conjunctiva. Ophthalmology 2011; 118:747-754. This study proposes a grading system to characterize conjunctival scarring and inflammation, representing the first time confocal microscopy has been applied to trachoma.
37. Hu VH, Weiss HA, Massae P, et al. In vivo confocal microscopy in scarring trachoma. Ophthalmology 2011; 118:2138-2146.
38. West S, Munoz B, Mkocha H, et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 2005; 366:1296-1300.
39. Burton M, Holland M, Makalo P, et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 2005; 365:1321-1328.
40. West SK, Munoz B, Mkocha H, et al. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania. J Infect Dis 2011; 204:268-273. This study examined communities after multiple years of MDA in previously hyperendemic areas (average prevalence 51% in children under 5). A regression model predicts that more than 7 years of annual treatment is needed to achieve control of hyperendemic communities. Further examination of antibiotic coverage and its relation to the reduction of infection can provide insight into effective treatment strategies.
41. Gebre T, Ayele B, Zerihun M, et al. Comparison of annual versus twice-yearly mass azithromycin treatment for hyperendemic trachoma in Ethiopia:
42. West SK, Stare D, Mkocha H, et al. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma? Invest Ophthalmol Vis Sci 2011; 52:6040-6042.
43. Keenan JD, Moncada J, Gebre T, et al. Chlamydial infection during trachoma monitoring: are the most difficult-to-reach children more likely to be infected? Trop Med Int Health 2011. doi: 10.1111/j.1365-3156.2011.02919.x.
44. Ayele B, Gebre T, Moncada J, et al. Risk factors for ocular Chlamydia after three mass azithromycin distributions. PLoS Negl Trop Dis 2011; 5:e1441.
45. Bowman RJ, Sillah A, Van Dehn C, et al. Operational comparison of singledose azithromycin and topical tetracycline for trachoma. Invest Ophthalmol Vis Sci 2000; 41:4074-4079.
46. Ayele B, Gebre T, House JI, et al. Adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am J Trop Med Hyg 2011; 85:291-294.
47. Cochereau I, Goldschmidt P, Goepogui A, et al. Efficacy and safety of short duration azithromycin eye drops versus azithromycin single oral dose for the treatment of trachoma in children: a randomised, controlled, double-masked clinical trial. Br J Ophthalmol 2007; 91:667-672.
48. Yagci A, Palamar M. Long-term results of tarsal margin rotation and extended posterior lamellae advancement for end stage trachoma. Ophthal Plast Reconstr Surg 2011. doi: 10.1097/IOP.0b013e318229b50e.
49. Reacher M, Huber M, Canagaratnam R, Alghassany A. A trial of surgery for trichiasis of the upper lid from trachoma. Br J Ophthalmol 1990; 74:109-113.
50. Habtamu E, Rajak SN, Gebre T, et al. Clearing the backlog: trichiasis surgeon retention and productivity in northern Ethiopia. PLoS Negl Trop Dis 2011; 5:e1014.
51. Reacher MH, Munoz B, Alghassany A, et al. A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol-Chic 1992; 110:667-674.
52. Rajak SN, Habtamu E, Weiss HA, et al. The clinical phenotype of trachomatous trichiasis in Ethiopia: not all trichiasis is due to entropion. Invest Ophthalmol Vis Sci 2011; 52:7974-7980.
53. Rajak SN, Habtamu E, Weiss HA, et al. Epilation for trachomatous trichiasis and the risk of corneal opacification. Ophthalmology 2012; 119:84-89.
54. Rajak SN, Habtamu E, Weiss HA, et al. Absorbable versus silk sutures for surgical treatment of trachomatous trichiasis in Ethiopia: a randomized controlled trial. PLoS Med 2011; 8:e1001137. This large surgical randomized clinical trial (RCT) found no difference in the risk of recurrent trichiasis after 1 year follow-up between absorbable and silk suture use. This is the only RCT in 2011 that examines surgical interventions for trachoma.
55. Maher MC, Alemayehu W, Lakew T, et al. The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field. PLoS ONE 2012; 7:e29407.
56. Dunne MW, Singh N, Shukla M, et al. A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India. Am J Trop Med Hyg 2005; 73:1108-1111.
57. Fry AM, Jha HC, Lietman TM, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 2002; 35:395-402.
58. Keenan JD, Ayele B, Gebre T, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis 2011; 52: 883-888. In a cohort of 35 052 children above 1 year of age and 5507 children 1-5 years of age, there was a reduction in all-cause mortality in children who received azithromycin [odds ratio (OR) 0.35, 95% confidence interval (CI) 0.17-0.74]. This suggests that MDAs have secondary implications that extend beyond trachoma control.
59. Coles CL, Levens J, Seidman JC, et al. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J 2011. doi: 10.1097/INF.0b013e31824155c9
60. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002; 2:25-32
61. Rudan I, Boschi-Pinto C, Biloglav Z, et al. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008; 86:408-416
62. Coles CL, Seidman JC, Levens J, et al. Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg 2011; 85:691-696.
63. Hassan A, Ngondi JM, King JD, et al. The prevalence of blinding trachoma in northern states of Sudan. PLoS Negl Trop Dis 2011; 5:e1027.
64. Chen H, Wu X, Wei M, et al. Changes in the prevalence of visual impairment due to blinding trachoma in Sichuan Province, China: a comparative study between 1987 and 2006. Ophthalmic Epidemiol 2011. doi: 10.3109/ 09286586.2011.615451.
65. Taylor Ac HR, English DR, Field MBA, et al. The prevalence of trachoma in a single community 1975-2007. Clin Experiment Ophthalmol 2011. doi: 10.1111/j.1442-9071.2011.02672.x.
66. Lietman TM, Gebre T, Ayele B, et al. TANA Study Group: the epidemiological dynamics of infectious trachoma may facilitate elimination. Epidemics 2011; 3:119-124.
67. Gaynor BD, Miao Y, Cevallos V, et al. Eliminating trachoma in areas with limited disease. Emerging Infect Dis 2003; 9:596-598.
68. Solomon A, Holland M, Alexander N, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004; 1962-1971.
69. Roba AA, Wondimu A, Patel D, Zondervan M. Effects of intervention with the SAFE strategy on trachoma across Ethiopia. J Epidemiol ommun Health 2011; 65:626-631.
70. Koroma JB, Heck E, Vandy M, et al. The epidemiology of trachoma in the five northern districts of Sierra Leone. Ophthalmic Epidemiol 2011; 18:150-157.
71. Gower EW. Solving the trachoma elimination puzzle, one piece at a time. Lancet 2011. doi: 10.1016/S0140-6736(11)61707-8.
72. Frick KD, Colchero MA, Dean D. Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis. Vaccine 2004; 22:689-696.
73. Medina NH, Lopes M, de F, et al. Survey of trachoma within school students in the state of Roraima. Brazil Ophthalmol 2011; 118:1938-1943.
74. Montgomery MA, Desai MM, Groce NE, Elimelech M. Relationship between distance to social gathering facilities and risk of trachoma for households in rural Tanzanian communities. Soc Sci Med 2011; 73:1-5.
75. Koukounari A, Touré S, Donnelly CA, et al. Integrated monitoring and evaluation and environmental risk factors for urogenital schistosomiasis and active trachoma in Burkina Faso before preventive chemotherapy using sentinel sites. BMC Infect Dis 2011; 11:191.
76. Stoller NE, Gebre T, Ayele B, et al. Efficacy of latrine promotion on emergence of infection with ocular Chlamydia trachomatis after mass antibiotic treatment: a cluster-randomized trial. Int Health 2011; 3:75-84.
77. Gebre T, Ayele B, Zerihun M, et al. Latrine promotion for trachoma: assessment of mortality from a cluster-randomized trial in Ethiopia. Am J Trop Med Hyg 2011; 85:518-523.
78. Kolaczinski JH, Robinson E, Finn TP. The cost of antibiotic mass drug administration for trachoma control in a remote area of South Sudan. PLoS Negl Trop Dis 2011; 5:e1362.
79. Kabatereine NB, Malecela M, Lado M, et al. How to (or not to) integrate vertical programmes for the control of major neglected tropical diseases in sub-Saharan Africa. PLoS Negl Trop Dis 2010; 4:e755.